Home > Category > Signaling Pathways > Protein Tyrosine Kinase/RTK > FLT3 > Quizartinib (AC220)

Quizartinib (AC220)

ChemLeader 98+%
Catalog No:CL2519 CAS No.:950769-58-1 MDLNo: Formula:C29H32N6O4S MW:560.67
Size Availability Price(USD) VIP Price (USD) Quantity

There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Chemical safety data sheet(MSDS)

Download MSDS
  • Product Overview
  • Related documents
  • Product details
  • Related literature
Product Overview
Product Name Quizartinib (AC220)
CAS950769-58-1
FormulaC29H32N6O4S
MW560.67
AppearanceWhite to off-white powder
Storage conditionDry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
Product details

Quizartinib (formerly also know as AC-220; AC-010220, Vanflyta) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.With IC50s of 1.1 nM and 4.2 nM, respectively, it inhibits FLT3 in MV4-11 and RS4EL11 cells. With respect to KIT, PDGFRα, PDGFRβ, RET, and CSF-1R, it demonstrates a ten-fold greater selectivity. Currently, Daiichi Sankyo is developing quizartinib to treat acute myeloid leukemia. Quizartinib (Vanflyta) was approved in 2023 by FDA for treating AML.

Related literature
Sorry, there is no relevant literature
Related
Sorry, no related items
Service
ChemLeader
021-58180488
Online service time: 9:00-18:00 on weekdays